SS
GLMD icon

Steve Schonfeld’s Galmed Pharmaceuticals GLMD Stock Holding History

Steve Schonfeld’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,899
Closed -$42.7K – 2336
2025
Q2 		$42.7K Sell
2,899
-250
-8% -$2.94K ﹤0.01% 1893
2025
Q1 		$36.3K Sell
3,149
-26
-0.8% -$511 ﹤0.01% 2080
2024
Q4 		$81K Buy
+3,175
New +$86K ﹤0.01% 1851
2018
Q3 		– Sell
-35
Closed -$595K – 878
2018
Q2 		$595K Buy
+35
New +$405K 0.03% 500

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Steve Schonfeld's GLMD Position: Q3 2025 in Review

Steve Schonfeld sold out of Galmed Pharmaceuticals (GLMD) in Q3 2025, closing a stake of 2,899 shares — an estimated $42.7K sold.

Steve Schonfeld first reported a position in GLMD in Q2 2018 and held it in 4 quarters. The position peaked at $595K in Q2 2018. 10 funds tracked by Wall St. Rank hold GLMD as of Q3 2025.

  • Steve Schonfeld reported no remaining Galmed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Steve Schonfeld sold 2,899 Galmed Pharmaceuticals shares in Q3 2025, an estimated $42.7K.
  • Steve Schonfeld first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Steve Schonfeld's Galmed Pharmaceuticals position peaked at $595K in Q2 2018.
  • 10 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.